Prolindox

Prolindox is a private biotechnology company founded in 2020 that is developing therapies aimed at enhancing intrinsic cellular defense mechanisms against oxidative damage. Its work is rooted in Herbert Weissbach's discovery of the methionine sulfoxide reductase system and focuses primarily on small molecules that upregulate protective anti-oxidative pathways. The company's lead focus is retinitis pigmentosa, for which its lead compound, sulindac, has received FDA orphan drug designation, and it also cites age-related eye diseases and cardiovascular ischemia-reperfusion injury as areas of interest. Prolindox additionally describes a gene therapy approach intended to increase methionine sulfoxide reductase enzyme levels in tissues. The company appears to be an early-stage, research-driven ophthalmology and oxidative stress biotech based in Boynton Beach, Florida.